<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 26-year-old man with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) and a history of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> developed <z:hpo ids='HP_0001409'>portal hypertension</z:hpo> accompanied by <z:hpo ids='HP_0002910'>abnormal liver function</z:hpo> and <z:hpo ids='HP_0002040'>esophageal varices</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>As his clinical course suggested the possibility of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, a titer of anticardiolipin antibody (aCL) was serially measured using an enzyme immunoassay with beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I as a cofactor </plain></SENT>
<SENT sid="2" pm="."><plain>The titer of aCL increased with the development of <z:hpo ids='HP_0001409'>portal hypertension</z:hpo>, and promptly decreased with the improvement of liver function just after <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> therapy </plain></SENT>
<SENT sid="3" pm="."><plain>The long-term course in this case suggests that aCL may cause <z:hpo ids='HP_0001409'>portal hypertension</z:hpo> associated with SLE </plain></SENT>
</text></document>